Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

By afschroeder • July 11, 2026

Peters S, Meyer ML, André F, Argilés G, Azizi AA, Banerjee S, Burgers S, Curigliano G, Drago JZ, Fontana E, Garon EB, Klümper N, Le Bescond L, Lopez-Rios F, Mountzios G, Passaro A, Paz-Ares L, Pistilli B, Powles T, Reguart N, Remon J, Schmelzle T, Skynner MJ, Smit E, Smyth E, Swanton C, Van Cutsem E, Loi S, Stahel RA. Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation. ESMO Open. 2026 Jul 10;11(8):108316. doi: 10.1016/j.esmoop.2026.108316. Epub ahead of print. PMID: 42431135.

Tags: Antibody–drug conjugate, Biomarker, Hematology/Oncology, Publications, research priorities, resistance, solid tumours

Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

Konecny GE, Lim PC, Santin AD, Gilbert L, Alvarez Secord A, Bessette P, Matulonis UA, Sen J, Hong J, Lytle GE, Bako E, Spunt SL,[...]

Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply

O'Reilly EM, Wolpin BM, Wainberg ZA. Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2026 Oct 22;395(16):1662. doi: 10.1056/NEJMc2611022. PMID: 42906097.

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

Leshchiner I, Medford AJ, Cha J, Kiedrowski LA, Niemierko A, Keenan JC, Dai CS, Spring LM, Moy B, Wander SA, Vidula N, Isakoff SJ, Juric[...]